ATLANTA, GA, August 19th, 2026 Organoids are powerful tools for studying complex human biology—but realizing their full potential requires new solutions that promote stable attachment and support reliable functional recordings. To strengthen organoid workflows, Axion BioSystems has entered into a distribution agreement with Swedish biotechnology company BioLamina. Customers can now purchase BioLamina’s Biolaminin® 332 LN (LN332), a human recombinant laminin cell culture matrix, with select Axion MEA plates.
“Organoid research is advancing quickly, and the tools surrounding these models must evolve alongside it,” said Stacie Chvatal, Vice President of Product Management at Axion BioSystems. “By bringing together BioLamina’s solutions for improved organoid attachment with Axion’s functional analysis technologies, this partnership helps researchers gain more meaningful data from increasingly complex models.”
In Axion’s internal testing, LN332 supported sustained organoid attachment to 3DMap MEAs during long-term experiments, consistent with laminin-332’s established role in cell adhesion. Axion has also updated its neural and cardiac organoid protocols with practical instructions for incorporating LN332 into MEA workflows. Together, the new offering and revised protocols simplify organoid preparation for MEA studies.
About Axion BioSystems
Axion BioSystems is a leading life sciences tools company focused on innovative live-cell assays used to study the function of cells in vitro for drug discovery and disease modeling. The team at Axion BioSystems is dedicated to continuing the advancement of new technologies that accelerate research and further the understanding of biological complexity outside of the body. Axion BioSystems is headquartered in Atlanta, Georgia, USA, and has offices in the Netherlands, the UK, and China.
